Related Experiment Video

Updated: Aug 19, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Multiple antiplatelet effects of clopidogrel are not modulated by statin type in patients undergoing percutaneous

Simon M G Smith1, Heather M Judge, Gary Peters

  • 1Cardiovascular Research Group, University of Sheffield, Clinical Sciences Centre, Northern General Hospital, Sheffield, UK.

Platelets
|March 15, 2005
PubMed

Insights

This study found that statin type and dose do not affect how well clopidogrel inhibits platelet function. Clopidogrel effectively reduced platelet aggregation and activation in patients undergoing percutaneous coronary intervention.

Area of Science:

  • Cardiovascular Pharmacology
  • Platelet Biology
  • Interventional Cardiology

Background:

  • Clopidogrel is a key antiplatelet medication used in patients undergoing percutaneous coronary intervention (PCI).
  • Statins are commonly prescribed to patients with cardiovascular disease, and some statins are metabolized by CYP3A4, the same enzyme that metabolizes clopidogrel.
  • Potential interactions between statins and clopidogrel could affect clopidogrel's efficacy.

Purpose of the Study:

  • To investigate whether statin type or dose influences clopidogrel's inhibition of platelet function.
  • To assess the impact of various statins on platelet aggregation, activation, and pro-coagulant activity in patients receiving clopidogrel therapy.

Main Methods:

  • Prospective, open, parallel group study involving patients undergoing elective PCI.
  • Patients received atorvastatin, simvastatin, pravastatin, fluvastatin, or no statin therapy.
  • Platelet function was assessed using optical aggregometry, whole-blood platelet counting, point-of-care systems, and flow cytometry to measure aggregation, pro-coagulant activity, P-selectin expression, and platelet-leukocyte conjugates.

Main Results:

  • Clopidogrel significantly inhibited platelet responses (aggregation, activation) over time, reaching steady-state inhibition by day 10, irrespective of the measurement technique.
  • No significant effect of statin type or dose was observed on any of the measured platelet function parameters at any time point.
  • Platelet pro-coagulant activity, P-selectin expression, and platelet-leukocyte conjugate formation were also unaffected by concomitant statin use.

Conclusions:

  • Statin therapy, regardless of type or dose, does not interfere with the antiplatelet effects of clopidogrel.
  • These findings suggest that concomitant use of statins does not compromise clopidogrel's efficacy in inhibiting platelet function in patients undergoing elective PCI.

More Related Videos

Microfluidics in Assessing Platelet Function06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.